Timothy Eugene Sullivan - 25 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
25 Apr 2022
Net transactions value
+$2,274,017
Form type
4
Filing time
17 Jan 2023, 19:00:46 UTC
Previous filing
14 Feb 2022
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -3,750 -3.6% $0.000000 99,653 25 Apr 2022 Direct F1
transaction APLS Common Stock Award $0 +27,488 +28% $0.000000 127,141 12 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -22,500 -100% $0.000000* 0 25 Apr 2022 Common Stock 22,500 $44.90 Direct F3, F4
transaction APLS Stock Option (Right to Buy) Award $2,274,017 +43,183 $52.66 43,183 12 Jan 2023 Common Stock 43,183 $52.66 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This represents a Restricted Stock Award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F3 This represents the cancellation of a performance stock option granted on 01/28/2021. The performance metrics were not met.
F4 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
F5 This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.